Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT)

X
Trial Profile

Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belatacept (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms BENEFIT
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 08 Jun 2022 Results assessing long-term allograft function between belatacept-based regimens and tacrolimus-based regimen up to five years from two clinical studies: BENEFIT and BENEFIT EXT presented at the 2022 American Transplant Congress
    • 08 Jun 2022 Results assessing the use of a contemporaneous external control group analysis as a supplement to the BENEFIT study's cyclosporine arm, presented at the 2022 American Transplant Congress.
    • 08 Jun 2022 Results assessing the performances of the iBox system to capture this hemodynamic effect to predict long term graft survival in patients under a CNI free regimen in two studies (BENEFIT & BENEFIT EXT) presented at the 2022 American Transplant Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top